- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem Resistant Enterobacterales (OP0595-6)
This study looks at new medicines for serious bacterial infections like complicated urine infections, pneumonia, and tummy infections. Researchers want to see if these new treatments work better and are safer than current standard care, especially for infections resistant to common antibiotics.
For: Complicated urinary tract infection (cUTI) · acute uncomplicated pyelonephritis (AP) · hospital acquired bacterial pneumonia (HABP)France · Czechia · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults (OP0595-5)
This study is testing new medicines for serious urine infections. It compares them to a standard medicine to see if they are safe and work well for adults with complicated urine infections or kidney infections, checking if they clear the infection and make patients feel better.
For: Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)Latvia · Slovakia · Bulgaria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICENTER, OPEN-LABEL, EVALUATOR-BLINDED, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SINGLE-DOSE INTRAVENOUS ORITAVANCIN FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
This study is looking at how safe a new medicine called Oritavancin (also known as ORBACTIV or KIMYRSA) is for children with serious skin infections. Researchers want to see if it causes any problems when given as a single dose through a drip.
For: Acute Bacterial Skin and Skin Structure InfectionsLatvia · Romania · Greece - AuthorisedTherapeutic confirmatory (Phase III)
ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections
This study looks at whether antibiotics before and after bladder botulinum toxin A injections can prevent urine infections. It's for adults with bladder problems from multiple sclerosis or spinal cord injury, who also have bacteria in their urine without symptoms.
For: Patients (male or female) ≥18 years old with Detrusor overactivity (DO) in multiple sclerosis (MS) or spinal cord injured (SCI).France